

**Open Access** 

**Mini Review** 

# Biochemical tale of CO in the vale of eye: a mini review

Jan mohammad Mir<sup>1\*</sup>, F.A. Itoo<sup>2</sup>, R. C. Maurya<sup>1</sup>

<sup>1</sup>Coordination, Bioinorganic and Computational Chemistry Laboratory, Department of P.G. Studies and Research in Chemistry and Pharmacy, Rani Durgavati University, Jabalpur, M.P., India.
<sup>2</sup>Department of Chemistry, Govt. Degree College, Udhampur (J&K), India

#### Article Info

**Received:** April 11, 2021 **Accepted:** April 15, 2021 **Published:** April 21, 2021

\*Corresponding author: Jan mohammad Mir, Coordination, Bioinorganic and Computational Chemistry Laboratory, Department of P.G. Studies and Research in Chemistry and Pharmacy, Rani Durgavati University, Jabalpur, M.P, India.

**Citation:** J. M. Mir, F.A. Itoo and R. C. Maurya. (2021) "Biochemical tale of CO in the vale of eye: a mini review", Ophthalmology and Vision Care, 1(2); DOI: http://doi.org/04.2021/1.1006.

**Copyright:** © 2021 Jan mohammad Mir. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly Cited.

# Abstract

Carbon monoxide (CO) is one of the biologically significant members of "gasotransmitters" known to have multiple roles in maintaining mammalian homeostasis. This molecule at non-optimal level is toxic for mammalian physiology. Like nitric oxide, this gaseous molecule found associated with metabolic pathways of heme-oxygenase, has profound implications on maintaining healthy eyesight. CO donors or CO-releasing molecules have also sound applications in normalizing Intra Ocular Pressure (IOP). Therefore, the CO is related with the ophthalmic control. In addition to rectify optical defects the antimicrobial efficiency of CO and its releasers represent fascinating area of research. Hence, the related compounds are supposed to act as a shield for both the infectious as well as the non-infectious eye defects. **Keywords:** Gasotransmitters; Ophthalmic diseases; CO; CORMs.

1. Introduction:

The scientific recognition of carbon monoxide (CO) and hydrogen sulphide (H<sub>2</sub>S) as bio-conjugated molecules sharing similar functional role as nitric oxide (NO) resultedin coining the term "gasotransmitters" for these molecules based on size, lipophilic character,half-life and several other features [1, 2].Even though these gases share a number of common features, they also possess dissimilar characteristics and display noteworthy interactions, which complicate the interpretation of their physiological activities.

Carbon monoxide (CO) has long been known as a dangerous gas for mammals and is called as a "silent killer" [3]. Carbon monoxide, when inhaled enters the bloodstream, formscarboxyhaemoglobin (COHb) at a rate 240 times greater than oxygen [4]. This reduces the oxygen transport ability and results in hypoxia [5]. Biologically, CO is considered as a by-product of heme oxygenase (HO) metabolism [6], and in the early stage of its biological exploration, CO was found as a chronic neurotransmitting agent [7]. Therefore, the further studies have altered the general perception of CO as a harmful molecule [8]. CO has now become an important molecule in the physical monitoring of many organ systems. In the last few decades, investigations related to CO have shown this gaseous molecule as a major chemical messenger.

The eye is one of the most sensitive parts of the brain. Any impairment in eye function requires high quality care. Among eye health problems intraocular pressure (IOP), cataract and retinal hypertension continue to remain as potential risk factors in treatment. Due to our growing interest towards pharmaceutical aspects of NO, CO and  $H_2S$  –based systems [9-17], and also, due to profound bio-actions of CO-tagged compounds on eye, herein a mini review in connection with CO-role in eye is reported. A historical view of the emergence of the term "gasotransmitter", within the production of CO in mammals, and to seek strong sponsors of CORMS (in the event of chronic biosynthesis and digestion) applicable in the most common eye-defects are the main objectives of this literature update.

# 2.Concept of "Gasotransmitters":

In general, gasotransmitters refer to the distinctive class of molecules like NO, CO and  $H_2S$ , responsible for communication amongst body cells for a particular biological action. Albeit, these molecules exist in solvated form while in biological medium, the

#### J Ophthalmology and Vision Care

respective differences in size, action, shape and bio-membrane interactions stems their multitude biological roles reported so far. The signal transduction pathway among such carriers may range from short to long distances to transmit the required information [18]. The properties and functional diversity found in these bioessential signalling molecules, therefore gave rise to coin a new term in reference to their biological relevance as "gasotransmitters".

## 2.1. Biological Production and Target of CO:

As per the metabolic pathways concerned with the CObiosynthesis, almost 14% of 500 µmol/day is obtained from lipid peroxidation and from photooxidation plus self-activation of cytochrome p-450. Bacteria and Xenobiotics also contribute the same minor percentage [19,20]. Major contribution (almost 86%) is generated by the erythrocyte-breakdown, wherein, the haemoxygenase (HO) catalyzes this oxidation. Like NOS, HO also exists in two isoforms,viz, HO-1 and HO-2. These are alsocalled as inducible and constitutive, respectively. Both the isoforms show same rate-limiting step while catabolizing heme, the difference lies with the regulation, amino acid sequence, and distribution in the tissues. Another HO has been recently identified and named as HO-3. This form of HO was detected in the several organs of rats. Till date no haem-degradation study has been reported for this newly detected HO-member [21]. The metabolic pathwayof HO-catalyzed haem oxidation involves several important stages as has been illustrated in Figure 1. In addition to CO other intermediatory products like of  $\alpha$ -meso-hydroxyheme, verdoheme, biliverdin (converts to bilirubin as excretory product conjugated by glucoronic acid shown in Figure 2) are also involved. [22,23]. The bioaction of HO-1 under stressful situation gets enhanced and the CO-production gets increased than the optimal value [24]. Therefore, suchan elevation in the concentration can be used as a sign convention medically to read the associated behaviour. The similar correlation has been found in several diseases wherein a patient is expected to suffer from stress and strain conditions.For instance in bronchiectasis, asthma, cystic fibrosis, hyperglycemia and other diseases CO level appears higher than the normal [25]. Hence, the detection level of CO because of inducible HO-1 can help in diagnosis of Figure 2: Chemical structure of Glucuronic acid pathophysiological state.



Figure 1: Oxidation of heme by heme oxygenase (HO) forming CO as a by-product.



## 3.CO Gasotransmitters in the Mission of Vision (Eye-Health Contribution):

Eye is one of the most important sense organs performing the function of vision through interacting with light, involving several physicochemical phenomena to memorize the surroundings, and therefore acts as a natural perception mediator to translate the observations to the brain. So, ultimately light-phenomenon to nerve actions, so many tissues collaborate to let such a complex process to happen. The physiology of eye is not restricted to a simple conduction process only but is subjected to the role of the gasotransmitters introduced vide supra. This section details the role of CO in maintaining a healthy eye, so is the title established as "the aim of CO gasotransmitter in the mission of vision".

## 3.1. Carbon monoxide, CORMS and the ocular system:

Glaucoma as discussed earlier is an optic neuropathy and is



Bucolo and Drago have recently updatedthat CO can furnish significant results of multiscale applications in treating eye impairments especially glaucoma [26]. CORM-3 as shown in Figure 3 is a famous CO-releaser when studied by Stagni et al. To find the role of CO in treating ocular system defects found that the compound resulted in lowering IOP in the rabbit animal models they selected for the experiment [34]. The drug potency in the respective tests indicated that after 24 hours of the consumption Figure 5: Chemical structure of CORM-A1 the IOP-lowering effect was seen for 30 minutes. Ingestion 1% dose was seen maximal six hour duration.



Figure 3: Chemical structure of CORM-3

From the results obtained by CO-based IOP-lowering it is expected that the action is because of soluble guanylyl cyclase(sGC)enhancement. CO-dependent sGC activation of sGC by CORM-3imparts an increase in the outflow of AqH as given in Figure 4, linking the pathways, TM with Schlemm's canal. It is expected that CO exhibits this action byreducing the volume of TM cell [35].



"European Glaucoma Society" suggesting the reduction of IOP as frequency of 38–714 per 1,00,000 persons [36]. CORM-A1 is an the first step, followed by medically supervised laser surgery of example of CO-releasing compounds tested for its effect on neural network called as "the trabecular meshwork" (TM) and uveoretinitis and is the first example of water-soluble COfiltering surgery of galucoma. As the main threat for glaucoma is releaser. Figure 5 and Scheme 1 may be referred for knowing the elevated IOP, hence is the first target to be corrected in the structural details and CO-releasing process. Nicoletti et al. [37] treatment plan [33]. Meanwhile CO is also expected to play a role showed that CORM-A1 is helpful in autoimmune responsive in





Scheme 1: Mechanism of CO release fromCORM-A1

## 4.Concluding Remarks and Future Outlook:

Gasotransmitters are, therefore, outstanding molecules having significant biological signalling role. Considering the fact that the scientific world is eager to design and develop molecular scaffolds in this context to be declared as medical or clinically relevant, so many questions are underway to be resolved. Halflife period, solubility, chemical environment effects, pH, thermodynamics and kinetics, all are among the queries being investigated in this field. The ocular diseases and the factors responsible for such impairments do contain mechanistic pathways half answered in relevance with CO. Drug delivery challenges, transportation, combinatory implications of drugs, optoelectronic effects, etc. need to be explored in a more deepened way. Moreover, could synthetic chemists bring forth a molecular system of synergetic effect in a view to declare molecular designs having potentiality of releasing 'CORMs?

#### **Disclosures:**

Figure 4: Diagram displaying the production and flow of aqueous Authors do not have any conflict of interest to declare.

#### Ethical Statement:

humour (AqH).

The yearly rate of incidence of uveitis (a sight-threatening

Aditum Publishing -www.aditum.org

All the data presented herein is original and extracted from 14. J. M. Mir, B. A. Malik, M. W. Khan and R. C. Maurya, literature sources under ethical rules and suitable citations have been made wherever necessary.

# **References:**

- 1. R. Wang, (2004) Signal transduction and gasotransmitters: NO, CO, and H<sub>2</sub>S in biology and medicine, Humana, Totowa (2004).
- 2. P. K.Allan and R. E. Morris, Medical Applications of Solid Nitrosyl Complexes, in "Nitrosyl Complexes in Inorganic Chemistry, Biochemistry and Medicine II, D. M. P. Mingos (Ed.), 154 Structure and Bonding, Springer, Springer-Verlag Berlin Heidelberg (2014).
- 3. L. Wu and R. Wang, Carbon monoxide: endogenous production, physiological functions, and pharmacological applications, Pharmacological Reviews, 57 (2005) 585-630.
- 4. C. G. Douglas, J. S. Haldane and J. B. Haldane, The laws of 18. A. K. Mustafa, M. M. Gadallaand S. H. Snyder. Signaling combination of haemoglobin with carbon monoxide and oxygen, The Journal of Physiology, 44 (1912) 275-304; J. B. 19. C. L. Hartsfield, Cross talk between carbon monoxide and S. Haldane, Carbon monoxide as a tissue poison, Biochemical Journal, 21 (1927) 1068-1075.
- 5. L. K. Weaver, Carbon monoxide poisoning, Crit. Care Clin., 15 (1999) 297-317; D. Gorman, A. Drewry, Y. L. Huang and C. Sames, The clinical toxicology of carbon monoxide, Toxicology, 187 (2003) 25-38.
- 6. T. Sjostrand, Early studies of CO production, Ann. NY Acad. Sci., 174 (1970) 5-10.
- 7. A. Verma, D. J. Hirsch, C. E. Glatt, G. V. Ronnett and S. H. Snyder, Carbon monoxide: a putative neural messanger, Science, 259 (1993) 381-384.
- 8. P. A. Rodgers, H. J. Vreman, P. A. Dennery and D. K. 22. R. Tenhunen, H. S. Marver and R. Schmid, Microsomal heme Stevenson, D. K., Sources of carbon monoxide (CO) in biological systems and applications of CO detection technologies, Semin Perinatol,18 (1994) 2-10.
- M. R. Mir, N. Jain, P. S. Jaget, W. Khan, P. K. Vishwakarma, 9 D. K. Rajak, B. A. Malik and R. C. Maurya, Urinary tract 24. R. Motterlini, A. Gonzales, R. Foresti, J. E. Clark, C. J. Green anti-infectious potential of DFT-experimental composite of analyzed ruthenium nitrosyl complex Ndehydroaceticacid-thiosemicarbazide, Journal of King Saud University-Science, 31 (2019) 89-100.
- 10. J. M. Mir, N. Jain, P. S. Jaget and R. C. Maurya. Density [Ru<sup>II</sup> (NO)(Salen)(Cl)] Functionalized Complex: computational, photodynamics and in vitro anticancer facets, Photodiagnosis and Photodynamic Therapy, 19 (2017) 26. F. Galassi, E. Masini, B. Giambene, F. Fabrizi, C. Uliva, M. 363-374.
- 11. J. M. Mir, N. Jain, B. A. Malik, R. Chourasia, P. K. Vishwakarma. Urinary tract infection fighting potential of newly synthesized ruthenium carbonyl complex of Ndehydroacetic acid-N'-o-vanillin-ethylenediamine, Inorg. 27. Chim. Acta, 467(2017) 80-92.
- 12. J. M. Mir, R. C. Maurya, A new Ru (II) carbonyl complex of 2-benzoylpyridine: Medicinal and material evaluation at the computational-experimental convergence. J. Chin. Adv. Mater. Soc., 6 (2018) 156-168.
- 13. J. M. Mir and R. C. Maurya, A gentle introduction to 28. L. K. Wareham, E. S. Buys and R. M. Sappington, The Nitric gasotransmitters with special reference to nitric oxide: Biological and chemical implications, Rev. Inorg. Chem., 38 (2018) 193-220.

- Molybdenum dinitrosyl Schiff base complexes of dehydroacetic acid and thiourea derivatives: DFTexperimental characterization and nosocomial anti-infectious implications, J. Chin. Chem. Soc., (2019)1-9.DOI:10.1002/jccs.201800337.
- the 15. J. M. Mir and R. C. Maurya, Experimental and theoretical insights of a novel molybdenum (0) nicotine complex containing CN and NO as co-ligands, J. Chin. Adv. Mater. Soc., 2018.
  - 16. J. M. Mir, R. C. Maurya. Nitric oxide functionalized molybdenum (0) pyrazolone Schiff base complexes: thermal and biochemical study, RSC Adv., 8(2018) 35102-35130.
  - 17. J. M. Mir and R. C. Maurya, Physiological and pathophysiological implications of hydrogen sulfide: A persuasion to change the fate of the dangerous molecule, J. Chinese Adv. Mater.Soc., 2018.
  - by gasotransmitters, Sci. Signal, 2 (2009) 1-8.
  - nitric oxide, Antioxid. Redox Signal, 4 (2002) 301-307.
  - 20. M. A. Gonzales and P. K. Mascharak, Photoactive metal carbonyl complexes as potential agents for targeted CO delivery, J. Inorg. Biochem., 133 (2014) 127-135; T. R. Johnson, B. E. Mann, J. E. Clark, R. F., Colin J. Green and R. Motterlini, Metal carbonyls: a new class of pharmaceuticals? Angew. Chem. Int. Ed., 42 (2003) 3722-3729.
  - 21. M. D. Maine, The heme oxygenase system: A regulator of second messenger gases, Annu. Rev. Pharmacol. Toxicol., 37(1997) 517-554.
  - oxygenase: Characterization of the enzyme, J. Biol. Chem., 1969, 244, 6388-6394.
  - 23. R. Schmid, A. F. McDonagh, ThePorphyrins, Vol. VI (Ed.: D. Dolphin), Academic Press, New York (1979) 257-293.
  - and R. M. Winslow, Heme oxygenase 1-derived carbon monoxide contributes to the suppression of acute hypertensive responses in vivo, Circ.Res., 83(1998) 568-577.
  - 25. T. R. Johnson, B. E. Mann, J. E. Clark, R. F., Colin J. Green and R. Motterlini, Metal carbonyls: a new class of pharmaceuticals? Angew. Chem. Int. Ed., 42(2003) 3722-3729.
  - Bolla and E Ongini, A topical nitric oxide-releasing dexamethasone derivative: effects on intraocular pressure and ocular haemodynamics in a rabbit glaucoma model, Br. J. Ophthalmol., 90 (2006) 1414-1419.
  - F. Impagnatiello, E. Bastia1, N. Almirante, S. Brambilla, B. Duquesroix, C. Kothe A. and M. V. W. Bergamini, Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma, British Journal of Pharmacology, 176 (2019)1079-1089.
  - Oxide-Guanylate Cyclase Pathway and Glaucoma, Nitric Oxide, 77(2018) 75-87;
  - 29. Q. Huang, E. Y. Rui, M. Cobbs, D. M. Dinh, H. J. Gukasyan,

J. A. Lafontaine, S. Mehta, B. D. Patterson, D. A. Rewolinski, P. F. Richardson and M. P. Edwards, Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase

- 30. D. Sambhara and A. A. Aref, Glaucoma management: relative value and place in therapy of available drug 36. E. Stagni, M. G. Privitera, C. Bucolo, G. M. Leggio, R. treatments, Ther. Adv.Chronic Dis., 5(2014)30-43.
- 31. J. Harding, Cataract, Biochemistry, Epidemiology and Pharmacology, Chapman & Hall, New York (1991).
- 32. J. A. Bawer, B. P. Booth, and H. L. Fung, Nitric oxide donors: Biochemical pharmacology and therapeutics, InNitric Oxide, Biochemistry, Molecular Biology and Therapeutic Implications, Editors, L. Ignarro, and F. Murad, Academic Press, New York, pp. 361-381 (1995).
- 33. R. Gaudana, H. K. Ananthula, A. Parenky and A. K. Mitra, Ocular Drug Delivery, The AAPS Journal, 12 (2010) 348-360.
- Implications glaucoma therapy, Pharmacology& for Therapeutics 130 (2011) 191-201.
- 35. A. Sommer, J. M. Tielsch, J. Katz, H. A. Quigley, J. D. Gottsch, J. Javitt and K. Singh, Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: the Baltimore eye survey,

inhibitors to lower intraocular pressure, J. Med. Chem., 58 (2015) 2821-2833.

Archives of Ophthalmology, 109 (1991)1090-1095.

- Motterlini, and F. Drago, A water-soluble carbon monoxidereleasing molecule (CORM-3) lowers intraocular pressure in rabbits, British Journal of Ophthalmology, 93 (2009) 254-257.
- 37. X. Gasull, E. Ferrer, A. Llobet, A. Castellano, J. M. Nicolás, J. Palés, and A. Gual, Cell membrane stretch modulates the high-conductance Ca2+-activated K+ channel in bovine trabecular meshwork cells, Invest. Ophthalmol. Vis. Sci., 44 (2003)706-714.
- 38. D. Wakefield, J. H. Chang, Epidemiology of uveitis, Int. Ophthalmol. Clin. 45 (2005) 1–13.
- 34. C. Bucolo and F. Drago, Carbon monoxide and the eye: 39. P. Fagone, K. Mangano, S. Mammana, E. Cavalli, R. D. Marco, M. L. Barcellona, L. Salvatorelli, G. Magro, F. Nicoletti, Carbon monoxide-releasing molecule-A1 (CORM-A1) improves clinical signs of experimental autoimmune uveoretinitis (EAU) in rats, Clinical Immunology, 157(2015) 198-204.